Berkshire Hathaway ( NYSE:BRK.A ) ( NYSE:BRK.B ) CEO Warren Buffett is widely considered as one of the greatest investors of all time. One of Buffett's keys to success -- and a core lesson learned from his mentor Benjamin Graham -- has been to invest with a so-called "margin of safety." This concept centers on the idea of buying stocks trading a substantial discount relative to their intrinsic value. While the intrinsic value of a stock means different things to different investors, one of the common themes across the galaxy of definitions for this time-tested investing concept is to focus on companies with strong free cash flows, a solid balance sheet, and a growing dividend program. By taking this approach, investors can essentially ignore the inherent volatility in the market from year to year and simply let the company's strong fundamentals do the heavy lifting, so to speak. Which Berkshire Hathaway holdings -- a.k.a. Warren Buffett stocks -- are the best buys during … [Read more...] about 2 Best Warren Buffett Dividend Stocks to Buy Now
Usmf health care
Stocks rarely go straight up. When they do, the uncommon occurrence is called a "parabolic move." In stock terminology, such as move is defined by a sudden and dramatic increase in buying volume, thereby causing the company's share price to rapidly rise in a manner that resembles a parabola. Oddly enough, this phenomenon has happened on a far more regular basis in 2021 than at any other time in the history of the U.S. stock market. The most recent examples are the explosive upward moves by shares of Donald Trump's social media-associated stocks, Digital World Acquisition ( NASDAQ:DWAC ) and Phunware ( NASDAQ:PHUN ) . Last week, Digital World Acquisition's shares rose by as much as 1,500%. Phunware's shares, for their part, posted a jaw-dropping intraday high of over 2,000% during a single trading session last week. This week, it might be biotech 's turn at the parabolic-move game. Shares of Aurinia Pharmaceuticals ( NASDAQ:AUPH ) and Ocugen ( NASDAQ:OCGN … [Read more...] about 2 Biotech Stocks That Could Go Parabolic This Week
The Dow Jones Industrial Average is an index made up of 30 of the largest and most influential companies on U.S. stock exchanges. The index has historically returned around 7.5% each year, so being up over 15% makes 2021 a year to celebrate. Not every stock in the Dow Jones has performed well. The three stocks we'll discuss are all down and have been since the beginning of 2021, despite the index being up so much. We'll look at each one to determine whether they represent an opportunity or are down for a good reason. 1. Amgen Biotech company Amgen ( NASDAQ:AMGN ) has been down about 7% since the beginning of 2021. The company develops and sells drugs aimed at inflammation, cancer, bone health, heart disease, and more. Image source: Getty Images. When a company invents a successful drug, its formula is patented, protecting it from direct competition for many years. Medications can cost millions of dollars to research and develop but can fail when tested in trials. A … [Read more...] about Is It Time to Buy the Dow’s 3 Worst Performing Stocks This Year?
Late last December, Amgen ( NASDAQ:AMGN ) announced that the U.S. Food and Drug Administration (FDA) had expanded Otezla's approval from moderate to severe plaque psoriasis to include mild to moderate cases. What prompted the FDA to expand Otezla's plaque psoriasis indication? And what will this label expansion contribute to the pharma company's revenue? Let's dive into Otezla's phase 3 clinical trial results and its potential addressable market to answer these questions. Image source: Getty Images. The first and only oral therapy for all severities Paraphrasing Healthline, plaque psoriasis is a chronic condition that results in red and itchy skin due to the body producing new skin cells too quickly. The severity of plaque psoriasis is determined by how much of the body's surface area is affected by the disease. Mildly severe cases of the condition cover less than 3% of the body's surface area. Moderate occurrence of the disease is considered as affecting between … [Read more...] about What Does This Label Expansion Mean for Amgen’s Shareholders?
Dividends can be a great source of passive income, and they can also help supercharge your portfolio's growth if you take advantage of automatic dividend reinvestment. In other words, no matter your investment style, dividend-paying stocks can help you reach your goals -- and one that looks like a particularly excellent option right now is Amgen ( NASDAQ:AMGN ) . AMGN data by YCharts Recent drug approvals will help boost top-line growth At first glance, Amgen's business doesn't look particularly strong. In the third quarter, its total revenue came in at $6.7 billion, representing a meager 4% year-over-year increase. One reason for that unimpressive growth is that some of its key products are now out of patent protection and facing off against biosimilars in the market. For instance, sales of Neulasta, which stimulates the production of infection-fighting white blood cells in cancer patients, decreased by 25% year over year in the third quarter to $415 million. … [Read more...] about 1 Top Dividend Stock to Buy and Hold in 2022 and Beyond
The healthcare industry isn't always known for record-high returns, but the resilience, stable growth, and often, dividends, that these companies deliver are a tremendous draw for investors of all trading styles looking to build their portfolios. However, as companies across all industries have faced extreme volatility in recent months, some healthcare stocks have been hit harder than others. Teladoc ( NYSE:TDOC ) is certainly one of them. In this segment of Backstage Pass , recorded on Dec. 22 , Fool contributor Rachel Warren explains her investing thesis for Teladoc and why the stock is still a top contender for long-term investors to consider right now. Rachel Warren : I'm going to go with another company that is in the same boat in the sense that the business is still looking really good, but boy, the market has not been kind to the stock, and that would be Teladoc. This is a company I have talked a lot about over the past few months. This is a company … [Read more...] about This Beaten-Down Healthcare Stock Could Skyrocket in 2022
As we begin 2022, many companies are still being impacted by the effects of the pandemic. At the top of that list is Teladoc Health ( NYSE:TDOC ) , the telehealth company that saw its usage and stock price surge during the height of the pandemic as patients needing medical care turned to its platform to see doctors virtually. Considering this backdrop, investors could expect to see Teladoc's results tapering off, fitting the company neatly into the pandemic stock narrative. However, the actual results over the past few quarters tell a different story. So should investors buy, sell, or hold Teladoc in 2022? Let's take a look. Image source: Getty Images. Continued strong growth In the third quarter of 2021, Teladoc reported year-over-year revenue growth of 81%, continuing a streak of sequential revenue growth since the beginning of 2019. On its own, the 81% revenue growth is excellent, but it's even more impressive considering that Q3 of 2020 featured growth of … [Read more...] about Teladoc Stock: Buy, Sell or Hold In 2022?
The idea of buying Teladoc Health ( NYSE:TDOC ) in 2022 may make some investors nervous because the telemedicine stock sank 54% last year. And performance this year isn't off to a brilliant start, either. The shares have lost about 14% since Dec. 31. Investors are worrying that patients may abandon telemedicine after the pandemic ends. And that would mean Teladoc's best days are behind it. If that's the case, how will the still-unprofitable company make it to profitability? These are risks. But I also see some clues indicating these risks may not take shape. In fact, there are three great reasons to buy shares of Teladoc right now. Image source: Getty Images. 1. It's more than just a COVID stock Some investors viewed Teladoc as a "coronavirus stock" because patients flocked to online medical appointments -- instead of in-person ones -- during the early days of the health crisis. And those investors were right. The pandemic gave Teladoc the opportunity to attract more … [Read more...] about 3 Reasons to Buy Teladoc in 2022
Since the stock market bottomed out in March 2020, investors have enjoyed historic gains. It took less than 17 months for the broad-based S&P 500 to double from its bear market low. Furthermore, the widely followed index came close to tripling its long-term average annual return in 2021. Despite this incredible outperformance, amazing deals remain. Patient investors who buy into innovative companies with clear-cut competitive advantages have a real chance to see their initial investment compound many times over. If you have cash ready to invest and are willing to let time be your ally, the following four stocks all have the tools to turn $100,000 into $1 million by 2030. Image source: Getty Images. Teladoc Health There's no sugarcoating it: telehealth giant Teladoc Health ( NYSE:TDOC ) was one of 2021's biggest disappointments. After skyrocketing during the initial stages of the coronavirus pandemic, concerns about larger-than-expected losses tied to its … [Read more...] about 4 Stocks That Can Turn $100,000 Into $1 Million by 2030
For more than a decade, growth stocks have been the talk of Wall Street. Historically low lending rates have rolled out the red carpet for fast-paced companies and allowed them to borrow cheaply in order to hire, acquire, and innovate. But what you might not realize is that value stocks have actually outperformed growth stocks over the very long run. Since value stocks are profitable and time-tested, they're the perfect place for patient investors to put their money to work. Below are five value stocks that could make you richer in 2022. Image source: Getty Images. General Motors The days of General Motors ( NYSE:GM ) being just another stagnant auto stock are gone. The electrification of automobiles has placed a multi-decade growth opportunity on the company's doorstep, and it'll undoubtedly run with it. In June, General Motors announced plans to up its investments in electric vehicles (EVs), autonomous vehicles, and batteries to $35 billion by 2025 . The … [Read more...] about 5 Value Stocks That Can Make You Richer in 2022